Do Additional Charges for Long-listed Medicines Depend Only on Patient Preference?

Charges for eligible originator medicines with generic counterparts, medical necessity, supply and patient explanations under the 2026 notices.

October 14, 2026Updated: October 13, 2026Naoya YokotaAbout 10 min read

Additional charges for eligible long-listed medicines do not follow from patient preference alone. Japan's 2026 notices distinguish medical necessity, pharmacy supply, and the information needed to understand costs and make a choice.

Health & Medicine Public Policy Evidence Social Design

X Facebook Threads

TL;DR

From June 2026, the special charge is equivalent to half the price difference and is separate from the ordinary insurance copayment.
Examine patient preference, medical necessity, and availability at the actual facility rather than deciding from a prescription mark alone.
Separate the formal conditions for sufficient information and free choice from the process of checking explanations at the counter.

The header is an AI-generated conceptual image, not a photograph of an actual patient or pharmacy. This article examines the system and explanations, without determining an individual's prescription, medicine change, benefit eligibility, or bill.

What Is Happening

Separate the additional charge applying from June 2026 from notices with future effective dates.

The Charge Fraction and the Final Bill

Choosing a familiar medicine can involve a charge separate from the ordinary insurance copayment. A is an originator medicine with a generic counterpart. For this scheme, the definition also includes so-called quasi-originator products approved on or before 30 September 1967 that have a generic counterpart with a different price. For eligible products under the relevant conditions, including patient preference, a special charge is handled through . Describing this as a uniform surcharge on all originator medicines overlooks eligibility and conditions.

The says the special charge is equivalent to half the price difference. The price difference is between the eligible originator medicine and the generic medicine used for comparison. The special charge is paid separately from the ordinary insurance copayment, with consumption tax added.

Where several generic medicines exist, the comparison uses the highest generic price. Rounding also means that simply halving the difference does not necessarily produce the final bill. Neither “pay half the originator's price” nor “all medicine copayments become half” accurately describes the official explanation.

An explanation at the counter needs to identify the compared prices and distinguish this charge from the insurance copayment. Other consultation and dispensing costs should not be grouped together and called the system's additional charge. A comparison of total bills alone cannot identify which cost changed.

This article proposes an explanation format that shows the comparison prices, special charge, and insurance copayment as separate items. It does not claim that every facility uses the same document. Its purpose is to help establish what the figures shown to a patient represent.

Notice Dates and Dates of Application

The prescribing and dispensing notice dated 27 March 2026（外部サイト、新しいタブで開きます） describes application from 1 June. As of this article's reference date, 13 October 2026, current information should be read with that effective date in view.

By contrast, the calculation communication dated 30 September（外部サイト、新しいタブで開きます） sets out calculations applying from 1 March 2027. A newly published document does not mean its calculations already apply to October 2026 bills.

Eligible-product lists also have applicable periods. The official page separates April and May lists from those applying from June. Rather than use an old article's attached table to decide a current product's treatment, return to documents matching the medicine and prescribing or dispensing date. This article has not checked every listed product and does not determine eligibility for individual brands.

Staff sharing documents could record the issue date and together so later readers can distinguish them. Publication order alone can mix future changes with those already in effect. Updating an explanation requires establishing the date of the service being described.

Background & Context

Read the three categories of combined care and the conditions for long-listed medicines.

Three Categories for Combining Insured and Uninsured Care

Japan's provides benefits for the basic insured portion when specified uninsured care is combined with insured care. The ministry's system explanation（外部サイト、新しいタブで開きます） distinguishes evaluation care, , and selected care.

Evaluation care assesses matters such as safety and effectiveness toward future insurance inclusion. Selected care does not assume future insurance inclusion and involves a special charge for an option chosen by the patient. Room upgrades are among its categories, but their particular conditions cannot simply be transferred to medicine selection.

Patient-requested care, including pathways concerning medicines not approved in Japan, is a separate framework originating in a patient's request. The ministry’s patient information（外部サイト、新しいタブで開きます） explains its review period and costs. The additional charge discussed here is not the same as review procedures for using an unapproved medicine.

Distinguishing the categories changes the reasons for uninsured charges and the documents to examine. None means that ordinary insurance also pays all uninsured expenses. Saying that care “can be combined with insurance” does not settle its cost; identify the insured portion and what carries a separate charge.

A change to one additional charge does not establish an equivalent change across public health insurance. Discussing benefit scope requires specifying the care or medicines affected. This comparison helps readers examine cost explanations; it does not establish the effects or future shape of the whole system.

Conditions Beyond Patient Preference

Section 30 of the implementation conditions dated 27 March 2026（外部サイト、新しいタブで開きます） requires sufficient information, free choice, and consent. It also distinguishes recognized medical necessity and difficulty providing a generic medicine at the particular facility. Recording that a patient preferred a medicine does not alone establish that these conditions were examined.

The notice excludes inpatients from this form of selected care for long-listed medicines. Eligible products also have specific requirements. All prescriptions and all originator medicines therefore cannot be treated alike. A general percentage and the conditions applying to an individual bill need separate explanations.

The order of examination matters too. Rather than begin and end with the fraction, establish product eligibility and the treatment of medical necessity or supply constraints. This article explains those distinctions without suggesting that individuals can determine medical necessity from a notice alone. Professional judgments and information conveyed to the patient are distinct matters.

Reading the Structure

Examine costs, medical necessity, supply, and explanations to the patient.

Preference Checks from Prescribing to Dispensing

The prescribing and dispensing notice calls for prescribers to explain sufficiently that generic options are available and that preferring a long-listed medicine may produce a special charge. Pharmacists at the dispensing pharmacy also explain these matters and check preference. Recording a preference during prescribing differs from explaining the options again at the pharmacy.

The prescription fields for “no substitution, medically necessary” and “patient preference” record different reasons. Medical necessity preventing substitution and a preference following explanation should not be combined as equivalent reasons for an additional charge. A mark alone does not establish what the pharmacy can supply.

The notice says that where the pharmacy cannot provide a generic medicine, dispensing the long-listed medicine does not constitute a choice based on patient preference and remains covered by insurance benefits. It also describes a patient choosing a generic after an explanation at dispensing, despite an earlier preference mark. A recorded preference should not be read as an irreversible choice.

Supply conditions concern the facility actually dispensing the medicine. The July 2024 explanatory questions and answers（外部サイト、新しいタブで開きます） also discuss availability and medical necessity. General information about nationwide shortages does not establish whether a particular pharmacy can provide an alternative.

Examine each condition

Preference: Choice after receiving information
Medical necessity: Reasons judged by professionals
Supply: Availability at the actual facility

Avoid conflation

Preference: A mark alone does not settle it
Medical necessity: Different from personal preference
Supply: National information is insufficient

This reading framework follows distinctions in the official notices. It is not a procedure for diagnosis, medicine substitution, or calculating an individual's bill.

Figure 2. Separate preference, medical necessity, and supply

Explanations Before Choosing and Records After Payment

The implementation conditions require a clear, understandable display of the system's purpose and special charge within the facility. Website publication is generally required too, with separate treatment for facilities that have no website under their own management. Having published information on paper and online does not establish that a patient understood it before choosing.

When collecting the charge, a facility must issue a receipt clearly distinguishing the insurance copayment from the special charge. This helps readers examine costs later, but a receipt after payment cannot alone establish the prior explanation and consent process. Information before choosing and records after payment have different roles.

This article proposes examining explanation materials for separately readable information about available medicines, charge conditions, medical necessity, supply, and where to ask questions. It adds no new legal requirement and does not describe a measured improvement already achieved at service counters.

One possible method would check whether a person receiving an explanation can restate the difference between the ordinary copayment and special charge. Staff time and a place for consultation would also need consideration. Adding information does not by itself establish a reduction in differences in understanding.

Where preferences change after an explanation, evaluation should not be limited to an increase in generic substitutions. There is room to examine what information the patient learned and checked before deciding. A person who retained the same medicine cannot automatically be classified as someone the explanation failed to reach. The chosen medicine and understood information require different examination.

Evidence on Actual Burdens

How income and access to someone to consult affect choices is a question worth examining. The notices read for this article, however, set out conditions and explanations. They do not measure how much inequality increased or how much explanations improved understanding.

An investigation would need to distinguish cost, medical necessity, facility supply, and the timing of explanations and consultations. Counts of changed preferences alone cannot reveal whether someone accepted an explanation, could not afford the charge, or faced a change in available medicines. Consider what a recorded choice represents by examining how it was recorded; the existing data-literacy guide（このサイトの記事） explains population, sample, and bias when considering who is represented in a survey.

Research proposals also need to distinguish records needed for care from information collected for research. What question is being answered, who will be asked, the burden of answering, and the information's use all need consideration. A proposal adding work at the counter requires examining staff time before its method of improving explanations can be compared. These are proposed considerations, not completed research findings.

Remaining Questions

Ask who checks the information received before choosing and the burden of consultation.

What information about available medicines and charges reaches a patient before preference is recorded? Even where notices distinguish medical necessity and supply, understanding requires a separate check, including who explains any difference between prescribing and dispensing and provides consultation time. Beyond recording the result of a choice, how can the information received before making it be examined?

What can differences in bills establish about additional burdens? Where eligible products, ordinary copayments, medical necessity, or supply conditions differ, comparing amounts alone cannot establish the conditions under which someone chose. To investigate the system's purpose and changes experienced at the counter separately, how should the burden of asking patients and the use of their information be considered when examining explanation timing and consultation?

How can staff updating explanation materials after a revised notice check dates of application with staff who explain the system at service counters? A new notice requires checking dates against information on paper, websites, prescriptions, and receipts so future calculations do not enter current billing explanations. Alongside a record that an explanation was delivered, how far can checking whether patients have somewhere to ask questions establish the conditions supporting choice?

After explanation materials are replaced, can successors distinguish what the earlier materials conveyed from questions the patient still had? Outstanding checks need to be passed on without being recast as records of consent, including time and space to ask patients which parts of an explanation they understood. Rather than fill in reasons for withheld questions with staff assumptions, how can the conditions for asking be examined?

References

Patient-Requested Care Scheme (title translated by this article) — Ministry of Health, Labour and Welfare (checked 13 October 2026). Ministry of Health, Labour and Welfare, patient information (Japanese)

Selected Care for Originator Medicines with Generic Counterparts — Ministry of Health, Labour and Welfare (checked 13 October 2026). Ministry of Health, Labour and Welfare

Combined Insured and Uninsured Care System — Ministry of Health, Labour and Welfare (checked 13 October 2026). Ministry of Health, Labour and Welfare

Revision of Implementation Conditions for Display Information and Medicines under Combined Care (title translated by this article) — Ministry of Health, Labour and Welfare, Health Insurance Bureau (27 March 2026). Notice 0327 No. 6

Revision of Prescribing and Dispensing of Long-listed Medicines — Ministry of Health, Labour and Welfare, Health Insurance Bureau (27 March 2026). Notice 0327 No. 9

Questions and Answers on Prescribing and Dispensing Long-listed Medicines, Part 1 — Ministry of Health, Labour and Welfare, Medical Economics Division (12 July 2024). Administrative communication

Revision of Calculation of Selected-care Charges for Prescribing and Dispensing Long-listed Medicines (title translated by this article) — Ministry of Health, Labour and Welfare, Medical Economics Division (30 September 2026). Administrative communication

Reference Books

Related reading on medicine as a social institution includes 医療の選択 (岩波新書) (Choices in Healthcare; title translated by this article)（外部サイト、新しいタブで開きます）. The publisher-registered bibliographic details and contents（外部サイト、新しいタブで開きます） were checked, but the book's body and chapter conclusions are not quoted. Published in 2014, it is not evidence for the 2026 conditions discussed here; the ministry's documents above provide that evidence.

医療の選択 (岩波新書)

桐野高明 (2014)

View on AmazonPR

Statistics cited in this article

1Ministry of Health, Labour and Welfare, selected care for long-listed medicines（from June 2026） Open source
2Ministry of Health, Labour and Welfare, communication on calculating long-listed medicine charges（30 September 2026） Open source

Questions to Reflect On

What information about available medicines and costs reaches a patient before preference is recorded?
How can the explanation and consultation process be examined alongside billed amounts?

Key Terms in This Article

Patient-Requested Care: A Japanese scheme for combining insured care with care outside insurance, initiated by a patient's request and subject to checks of safety, effectiveness and an implementation plan to collect evidence for possible future insurance coverage. The uninsured portion is generally paid by the patient; requested treatment is not guaranteed.
Selected Care: A category within Japan's combined insured and uninsured care system, covering specified options such as room upgrades and eligible long-listed medicines. It differs from evaluation care intended to assess future insurance inclusion; eligibility and additional charges depend on the applicable conditions.
Long-listed Medicine: An originator medicine with a generic counterpart. This scheme also includes so-called quasi-originator products approved on or before 30 September 1967 that have a generic counterpart with a different price. Japan's additional selected-care charge applies to specified eligible products and conditions, rather than automatically to every such medicine. Medical necessity and supply conditions also require examination.
Date of application: The date from which a provision applies to covered persons or activities. Its scope, transitional arrangements and amendments also require checking.
Combined Insured and Uninsured Care System: A Japanese health-insurance framework allowing benefits for the basic insured portion when specified uninsured care is combined with insured care. It has three categories: evaluation care, patient-requested care, and selected care. It does not make the uninsured portion an insured expense.

X Facebook Threads

Ask about this article

Get new columns by email

1-2 social structure analysis columns per week. Free to subscribe.

Join ISVD's activities?

Sign up to receive the latest research and activity reports. Feel free to reach out about collaboration or project participation.

Join Contact Us

Support ISVD’s research and activities

Support ISVD’s research and publications with JPY5,000 per year. There is no automatic renewal.

Become a supporting member About supporting membership

Menu

About

Activities & Support

Platforms

Join & Contact

Do Additional Charges for Long-listed Medicines Depend Only on Patient Preference?